The Department of Health and Human Services Food and Drug Administration (FDA) awarded a single-award indefinite delivery contract to Harvard Pilgrim Health Care Inc., a non-profit healthcare organization, to provide services supporting the FDA's Sentinel Initiative for post-market medical product safety surveillance. The contract has a ceiling value of $275 million and a period of performance through September 2025.
Under this contract, Harvard Pilgrim will operate the Sentinel Operations Center, Innovation Center, and support community outreach to enhance the FDA's ability to monitor drug and medical device safety using real-world data. Task orders issued to date, worth over $50 million, include providing data analytics, epidemiological research, and program management services related to pregnancy safety monitoring, negative control tool development, and expanding Sentinel's electronic health data sources and methodological capabilities. This contract builds upon Harvard Pilgrim's prior experience supporting the FDA, Centers for Disease Control and Prevention, and National Institutes of Health through prime contracts and grants for public health and health services research.
Generated 7/27/24, 9:06 AM